Format

Send to

Choose Destination
J Thromb Haemost. 2019 Jun;17(6):896-900. doi: 10.1111/jth.14433. Epub 2019 Apr 25.

GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis.

Author information

1
School of Life Sciences, University of Lincoln, Lincoln, UK.
2
Haematology Department, Federico II University, Naples, Italy.
3
Histopathology Department, Nottingham University Hospital, Nottingham, UK.
4
Northwestern University, Department of Medicine, Hematology/Oncology, Chicago, IL, USA.
5
School of Biological Sciences, Queen's University Belfast, Belfast, UK.

Abstract

Essentials The BCR-ABL negative myeloproliferative neoplasms are subjected to unknown phenotypic modifiers. GATA-1 is upregulated in ET patients, regardless of treatment regimen or mutational status. Myelofibrosis (MF) megakaryocytes displayed decreased GATA-1 staining. GATA-1 may have utility as a diagnostic marker in ET and in its differential diagnosis from MF. ABSTRACT: Background The BCR-ABL-negative myeloproliferative neoplasms, i.e., polycythemia vera, essential thrombocythemia (ET), and myelofibrosis (MF), are characterized by mutations in JAK2, CALR, or MPL. However, an as yet unknown factor drives the precise disease phenotype. The hematopoietic transcription factor GATA-1 and its downstream targets NFE2 and FLI1 are responsible for determining erythroid and megakaryocyte lineages during hematopoietic stem cell differentiation. Previous studies have demonstrated a low level of GATA-1 expression in megakaryocytes from patients with MF. Objectives and methods The expression of GATA-1, NFE2 and FLI1 was studied for changes in the peripheral blood (PB) of ET patients. Peripheral blood samples were obtained from 36 ET patients, 14 MF patients, and seven healthy control donors. Total RNA from PB mononuclear cells (PBMCs) was extracted, and quantitative polymerase chain reaction was used to determine relative changes in gene expression. Protein levels of GATA-1 were also determined in bone marrow sections from ET and MF patients. Results GATA-1 mRNA was upregulated in ET patients, regardless of treatment regimen or mutational status. FLI1 expression was significantly downregulated, whereas NFE2 expression was unaffected by changes in GATA-1 mRNA levels. Megakaryocytes from ET patients showed increased protein levels of GATA-1 as compared with those from MF patients. Conclusions Our results confirmed, in PB, our previous data demonstrating elevated levels of GATA-1 mRNA in total bone marrow of ET patients. GATA-1 mRNA levels are independent of cytoreductive therapies, and may have utility as a diagnostic marker in ET and in its differential diagnosis from MF.

KEYWORDS:

GATA-1; biomarker; essential thrombocythemia; myelofibrosis

PMID:
30889303
DOI:
10.1111/jth.14433

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center